BioPharmSignal logoBioPharmSignal

Biotech News

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis (OCS)OculisClinical readout

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report topline results in June 2026 from DIAMOND Phase 3 registrational trials with OCS-01, which aims to be

Related news

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCSOculis2026-05-11 20:07 EST

Oculis Reports Q1 2026 Financial Results and Provides Company Update

EYPTEyePoint Pharmaceuticals2026-07-30 11:00 EST

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

OCGNOcugen2026-09-01 11:02 EST

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

EYPTEyePoint Pharmaceuticals2026-08-17 11:00 EST

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

BLTEBelite Bio2026-07-20 12:00 EST

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

PRQRProQR Therapeutics2026-06-25 10:25 EST

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

OKYOOKYO Pharma2026-09-09 11:00 EST

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYOOKYO Pharma2026-07-20 11:00 EST

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

OCULOcular Therapeutix2026-04-29 11:00 EST

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-09-17 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-08-24 08:00 EST

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

OCSOculis2026-08-14 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-08-10 07:30 EST

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Stock data

Close
9.98 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States